Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
PICALM
REST API REST API
Homo sapiens
PICALM is differentially expressed in 358 experiments: 150 organism parts: placenta, skeletal muscle, ... (148 more);, 249 disease states: normal, chronic myelogenous leukemia, ... (247 more);, 127 cell types 472 cell lines 47 compound treatments and 82 other conditions.
Synonyms CALM, CLTH
Orthologs PICALM (Gallus gallus)   picalml (Danio rerio)   Picalm (Rattus norvegicus)   PICALM (Bos taurus)   YAP1801 (Saccharomyces cerevisiae)   Picalm (Mus musculus)   picalm (Danio rerio)   ENSCING00000005999 (Ciona intestinalis)   YAP1802 (Saccharomyces cerevisiae)   lap (Drosophila melanogaster)   NP_001164996.1 (Xenopus laevis)   PICALM (Canis familiaris)   (Compare orthologs)
InterPro Term ANTH, Epsin-like_N, Epsin_dom_N
Gene Ontology Term clathrin coat of coated pit, clathrin coat, protein binding, dendrite morphogenesis, intracellular, clathrin coat assembly, membrane, clathrin-coated vesicle, postsynaptic membrane, Golgi apparatus, clathrin binding, receptor-mediated endocytosis, protein complex assembly, receptor internalization, phospholipid binding, regulation of protein localization, intracellular membrane-bounded organelle, presynaptic membrane, vesicle-mediated transport, hemopoiesis, coated pit, nucleus, cytoplasmic vesicle, perinuclear region of cytoplasm, axonogenesis, positive regulation of transcription, DNA-dependent, endosome transport, clathrin heavy chain binding, AP-2 adaptor complex, regulation of endocytosis, negative regulation of receptor-mediated endocytosis, 1-phosphatidylinositol binding
UniProt Accession Q13492, A8MX97, Q4LE54, B4DLM1, E9PN05, E9PI56, E9PK13, E9PJT1, E9PKP6, E9PLJ8, F8VPG7
Gene-Disease Assocation LEUKEMIA, ACUTE MYELOID; AML
Search EB-eye ENSG00000073921
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-GEOD-1577, E-GEOD-3526, ... (31 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-5258, E-GEOD-4525, E-MEXP-1006, E-GEOD-18005, E-MTAB-62, ... (49 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-19639, E-GEOD-20081, E-GEOD-5823, E-GEOD-3529
HL-60
3
E-GEOD-5258, E-MTAB-37, E-GEOD-24147
SNU16
2
E-GEOD-15460, E-MTAB-37
H1
2
E-GEOD-1309, E-MTAB-62
K562
2
E-MTAB-37, E-GEOD-24147
MCF-10A
2
E-GEOD-14990, E-TABM-420
466 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-20677, E-TABM-34, E-GEOD-2822, E-GEOD-21909, ... (60 experiments)

Factor Value U/D Experiments
monocyte
1
3
E-GEOD-22373, E-MEXP-583, E-GEOD-11755, E-GEOD-5099
adipocyte
2
E-AFMX-5, E-TABM-145
CD8+ T cell
2
E-GEOD-6740, E-AFMX-5
plasma cell
2
E-GEOD-6691, E-MEXP-2360
1
2
E-TABM-145, E-TABM-130
CD105+ endothelial
2
E-AFMX-5, E-TABM-145
121 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-MEXP-1121, E-GEOD-1577, ... (72 experiments)

Factor Value U/D Experiments
colon carcinoma
3
E-MTAB-62, E-MTAB-37, E-GEOD-3726
lung adenocarcinoma
3
E-MEXP-231, E-MTAB-37, E-MTAB-62
control
1
3
E-GEOD-21912, E-GEOD-8121, E-GEOD-16728, E-GEOD-20602
gastric carcinoma
2
E-MTAB-37, E-GEOD-2685
choriocarcinoma
2
E-MTAB-37, E-MTAB-62
glioblastoma
2
E-GEOD-6014, E-GEOD-4290
243 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-5741, E-GEOD-1417, E-TABM-782, E-GEOD-5824, ... (29 experiments)

Factor Value U/D Experiments
ethanol
2
E-MEXP-2241, E-GEOD-3113
lipopolysaccharide
2
E-MEXP-1958, E-TABM-868
nickel(II) chloride hexahydrate
1
E-GEOD-6907
bis [(+)-tartrato] diantimonate (III) dipotassium trihydrate
1
E-GEOD-6907
unknown
1
E-GEOD-7307
ponasterone A
1
E-GEOD-3113
41 more value(s).


A rna yield

studied in E-TABM-325

Factor Value U/D Experiments
89.02
1
1
E-TABM-325
74.51
1
1
E-TABM-325


Agent
studied in E-GEOD-19519

Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd34
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-GEOD-2171, E-GEOD-21589, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-22513, E-MEXP-1251, E-GEOD-21374, ... (8 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-5999, E-GEOD-1614, E-GEOD-20033, E-MEXP-2359, E-GEOD-6236, ... (9 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-89, E-GEOD-19743, E-GEOD-7788, E-GEOD-3325, E-GEOD-22148, ... (9 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-MTAB-73, E-GEOD-4025, E-MEXP-1482, E-GEOD-7578, E-GEOD-20847, ... (8 experiments)

Genotype
studied in E-TABM-1029, E-MEXP-1996, E-GEOD-17476, E-GEOD-2466, E-TABM-868, ... (17 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-MEXP-1220, E-GEOD-5681, E-TABM-127, E-GEOD-20540, E-GEOD-20504, ... (11 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-5764, E-TABM-740, E-MEXP-1956, ... (44 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-GEOD-12254, E-MEXP-561, E-GEOD-17400, ... (6 experiments)

Injury
studied in E-GEOD-19743

Irradiate
studied in E-MEXP-2177

Karyotype
studied in E-GEOD-7214

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-GEOD-2004, E-LGCL-5

Phenotype
studied in E-GEOD-26495, E-GEOD-1309, E-GEOD-22309, E-GEOD-21750, E-GEOD-1657, ... (10 experiments)

Population
studied in E-MTAB-197, E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-10797, E-GEOD-19330, E-GEOD-18791, E-GEOD-10896, E-GEOD-17204 ... (5 experiments)

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-MEXP-548, ... (8 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-21374, E-MEXP-70

Sex
studied in E-GEOD-2466, E-GEOD-7540, E-GEOD-7307

Sirna
studied in E-GEOD-21575, E-GEOD-21574

Stimulation
studied in E-GEOD-20114, E-GEOD-23984, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996, E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-13818, E-GEOD-19815, E-GEOD-12198 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.407 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM